马法兰联合全身照射的自体骨髓移植治疗恶性淋巴瘤  

TBI,Melphalan with autologous bone marrow transplantation for malignant lymphomas

作　　者：崔秀珍[1] 刘玉忠[1] 杨兴纲 李丽庆[1] 任宝柱[1] 

机构地区：[1]天津肿瘤研究所肿瘤医院

出　　处：《中华血液学杂志》1996年第10期521-523,共3页Chinese Journal of Hematology

摘　　要：为探讨自体骨髓移植（ＡＢＭＴ）治疗恶性淋巴瘤的适应证及高效、低毒的预处理方案，对１１例有预后不良因素的恶性淋巴瘤进行ＡＢＭＴ治疗。１１例中初治１０例，复发１例，移植时中位年龄２７（１９～３７）岁。预处理方案主要为全身照射（８Ｇｙ）和以马法兰（Ｍｅｌ）为主的大剂量化疗（Ｍｅｌ１４０ｍｇ／ｍ￣２±Ｖｐ１６２００ｍｇ或＋Ａｒａ－Ｃ１ｇ／ｍ￣２±ＣＴＸ６０ｍｇ／ｋｇ）。造血重建后肿瘤局部补加照射２５～３０Ｇｙ。移植结果全部患者造血功能获得重建，无移植相关死亡。中位随访３５（１３～５０）个月，持续完全缓解率８１．８％，复发率１８．２％。本预处理方案的ＡＢＭＴ对高度恶性非霍奇金淋巴瘤和常规治疗反应不良的霍奇金病有良好疗效。Eleven patients with poor prognostic malignant lymphoma received autologous bone marrow transplantation(ABMT).Among them,10 were primary and 1 relapsed,with a median age of 27 years(ranged from 19 to 37 years).The conditioning regimens consisted of TBI(8Gy)and melphalan(140mg/m2)with or without etoposide(200mg)or cyclophosphamide(60mg/kg).All patients were successfully engrafted with no graft related death.The continuous complete remission rate and relapse rate were 81.8%and l8.2%,respectively,at a median followup of 35 months(ranged from 13 to 50 months).

关 键 词：骨髓移植 自体移植 淋巴肉瘤 马法兰 放射疗法 

分 类 号：R733.405[医药卫生—肿瘤]